This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genoptix, Clinical Data: Small-Cap Winners

NEW YORK ( TheStreet) -- Clinical Data (CLDA) was the biggest gainer among small-caps Monday afternoon, its shares soaring 55% to $23.30, after U.S. regulators approved its major depressive disorder treatment Viibryd. The biotech company said the drug would be available in U.S. pharmacies by the second quarter. Over 9 million shares changed hands.

Shares of Genoptix (GXDX) jumped 26% to $24.83 on heavy volumes after Swiss pharma giant Novartis (NVS) said it was acquiring the diagnostics laboratory for $470 million or $25 per share in an all cash deal.

Rexahn Pharmaceuticals (RNN) shot up 20% to $1.57 after Israel-based Teva Pharmaceuticals (TEVA) said it had acquired a 6% stake in the company at $1.69 per share.

Several solar stocks were shining on the bourses after Goldman Sachs added First Solar (FSLR - Get Report) to its conviction list. Shares of LDK Solar (LDK) were surging 10.5% to $14.53. Solarfun Power (SOLF), Trina Solar (TSL - Get Report) and ReneSola (SOL - Get Report) were also up sharply.

Shares of Depomed (DEPO) were recovering Monday after plunging last week, rising 7.2% to $6.23. The stock took a hit last week after it said that Abbot Laboratories (ABT) was reluctant to market its pain reliever drug.

Level 3 Communications (LVLT), Dot Hill Systems (HILL), Pluristem Therapeutics (PSTI) and ATP Oil and Gas (ATPG) were among the other major gainers on Monday.

-- Written by Shanthi Bharatwaj in New York

>To contact the writer of this article, click here: Shanthi Bharatwaj.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
LDK $0.00 0.00%
FSLR $63.43 0.00%
RNN $0.73 0.00%
SOL $1.77 0.00%
TSL $12.58 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs